

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : A61K 31/07, 31/355, C07C 35/18 C07D 311/04		AI	(11) International Publication Number: WO 90/10440 (43) International Publication Date: 20 September 1990 (20.09.90)
(21) International Application Number: PCT/US90/01259		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).	
(22) International Filing Date: 7 March 1990 (07.03.90)			
(30) Priority data: 320,401 8 March 1989 (08.03.89) US			
(71) Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).		Published <i>With international search report.</i>	
(72) Inventors: SHKLAR, Gerald ; 7 Chauncy Lane, Cambridge, MA 02138 (US). SCHWARTZ, Joel, L. ; 50 Redwood Road, Newton Centre, MA 02159 (US).			
(74) Agent: FURLONG, Robert, W.; Fish & Richardson, One Financial Center, Suite 2500, Boston, MA 02111-2658 (US).			

## (54) Title: COMPOSITION AND METHOD FOR INDUCING TUMOR REGRESSION



## (57) Abstract

Oral ingestion of a mixture of vitamin E and a carotenoid in a carrier induces regression of a tumor in a mammal.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Fasso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LJ	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

- 1 -

## COMPOSITION AND METHOD FOR INDUCING TUMOR REGRESSION

This invention relates to a method and composition for inducing regression of tumors with a mixture of vitamin E and a carotenoid, and pertains more 5 specifically to oral ingestion of a mixture comprising vitamin E and a carotenoid.

Vitamin E and  $\beta$ -carotene has each been reported individually to be capable of inducing regression of epidermoid carcinomas in vivo in mammals when injected 10 locally: Schwartz, et al. Biochem. Biophys. Res. Commun. Vol 136:1130-1135 (1986); Shklar et al. J.N.C.I. Vol 78:987-992 (1987); and, Schwartz et al. Nutr. Cancer. Vol 11:35-40 (1988).

It has now been found that a mixture of vitamin 15 E and a carotenoid such as  $\beta$ -carotene is remarkably effective in inducing regression of tumors such as epidermoid carcinomas in mammals when ingested orally by the mammal, whereas neither vitamin E nor  $\beta$ -carotene when ingested individually is effective.

20 The drawing is a graphical representation of the results of practicing the present invention (Group 2), as well as the results obtained with controls and with administration of vitamin E and  $\beta$ -carotene individually.

25 The term "vitamin E" as used in the present application is intended to include vitamin E from natural sources as well as pure alpha-tocopherol, alpha-tocopherol alkanoates in which the alkanoate has from one to five carbon atoms, such as acetate, propionate, 30 butyrate or valerate, and alpha-tocopherol acid malonate, succinate and glutarate. Among carotenoids which can be used are  $\beta$ -carotene,  $\alpha$ -carotene, and canthaxanthin.

- 2 -

The relative proportions of the two active agents, vitamin E and carotenoid, in the mixture may vary over a wide range from 1:10 to 10:1 by weight, preferably from 6:4 to 4:6 by weight. Any 5 pharmacologically acceptable carrier or vehicle adapted for oral ingestion by mammals may be employed in the composition such as vegetable oils or foodstuffs. The relative proportions of active agents and vehicle or carrier are not critical but may be adjusted as 10 convenient for administration of a dose of the desired size. Dosages may also vary over a wide range. Doses of the order of 3-4 mg./kg. body weight per day have been found to be effective in the case of a 1:1 by weight mixture of alpha-tocopherol acid succinate and  $\beta$ - 15 carotene; optimum doses in the case of any particular mixture can readily be determined by conventional procedures.

The following specific example is intended to illustrate more fully the nature of the invention 20 without acting as a limitation upon its scope.

Example

One hundred young male adult randomly bred Syrian hamsters (*Mesocricetus auratus*) (Lakeview Strain LVG, Charles river Breeding Laboratories) were fed 25 standard Purina Laboratory pellets and water ad libitum. The animals were 60-90 days of age and weighed 95-125g at the beginning of the test procedure. The animals were divided into five groups of 20 animals each and were housed five to a cage and maintained in a 30 controlled environment under standardized conditions of temperature and humidity with an alternating 12 h light-dark cycle. All animals had the right buccal pouches painted three times per week with a 0.5 % solution of 7,12-dimethylbenz(a)anthracene (DMBA) in

- 3 -

heavy mineral oil USP using a number 3 sable brush. Each painting left approximately 0.6 mg. of the DMBA carcinogen on the mucosal surface of the buccal pouch as determined by measurements using the same procedure with <sup>14</sup>C DMBA.

After 14 weeks there were moderate sized tumors in the right pouches of all the animals and carcinogen painting was stopped. The different groups were then treated as follows:

10      Group 1    no treatment  
        Group 2     $\beta$ -carotene 200 $\mu$ g and alpha-tocopherol  
                  acid succinate 200 $\mu$ g in 0.2 ml  
                  vegetable oil daily by mouth  
15      Group 3     $\beta$ -carotene 400 $\mu$ g in 0.2 ml vegetable  
                  oil daily by mouth  
        Group 4    alpha-tocopherol acid succinate 400  $\mu$ g  
                  in 0.2 ml vegetable oil daily by mouth  
        Group 5    0.2 ml vegetable oil vehicle only

20 In each case the material was inserted into the mouth of the animal by syringe. The buccal pouch of the animal was normally closed so that little or no topical application of the material to the tumors occurred. At 22 weeks the tumors in groups 1, 3, 4 and 5 were extremely large. Smaller tumors had coalesced so that one large, extensive mass was observed in all these animals, with diameters measuring from 10-26 mm. The animals in group 2 had one or more small tumors. The animals in groups 1, 3, 4 and 5 at 22 weeks were weak 25 and cachectic and four animals had died during the 21st week. It was decided at that time to sacrifice the animals in groups 1, 3, 4 and 5 in a carbon dioxide chamber for humane reasons and to extend the group 2

- 4 -

5 animals to 28 weeks. The animals in group 2 were continued with daily feeding of the mixture. There was gradual regression of the tumors until 28 weeks in the group 2 animals so that the tumor burden was lower at 10 that time than that at the start of the treatment at 14 weeks as shown in the drawing. Several of the animals in group 2 at 28 weeks had no grossly visible tumors, although several other animals had tumors larger than those at 14 weeks. The group 2 animals were then 10 sacrificed.

15 The right buccal pouches of all animals at death were photographed and the tumors measured in each animal. The right pouches were excised and sections of each were fixed in 20% formalin, sectioned in paraffin and stained with hematoxylin and cosin. Cervical lymph nodes were dissected with adjacent tissue and also prepared for histologic study.

20 Microscopic evaluation demonstrated all tumors to be epidermoid carcinomas. At 22 weeks many of the group 1, 3, 4 and 5 animals had metastatic spread to cervical lymph nodes (about 40%). No tumor was found in cervical lymph nodes in any group 2 animals after 28 weeks.

25 The tumor burden in cubic millimeters for each group is shown in the plot of the drawing for 14 weeks and 22 weeks, and the burden for the group 2 animals is also shown at 28 weeks.

The results clearly show the remarkable effectiveness of the present invention.

- 5 -

CLAIMS:

1        1. A composition comprising vitamin E and a  
2        carotenoid in proportions from 1:10 to 10:1 by weight  
3        together with a pharmacologically acceptable carrier  
4        adapted for oral ingestion by mammals.

1        2. A composition as claimed in claim 1 in which  
2        said proportions are from 4:6 to 6:4 by weight.


1        3. A composition as claimed in claim 1 in which  
2        said vitamin E is in the form of alpha-tocopherol acid  
3        succinate and said carotenoid is  $\beta$ -carotene.

1        4. The method of inducing regression of a tumor in  
2        vivo in a mammal having said tumor which comprises  
3        administering to said mammal by oral ingestion the  
4        composition claimed in claim 1.

1        5. The method of inducing regression of a tumor in  
2        vivo in a mammal having said tumor which comprises  
3        administering to said mammal by oral ingestion the  
4        composition claimed in claim 2.

1        6. The method of inducing regression of a tumor in  
2        vivo in a mammal having said tumor which comprises  
3        administering to said mammal by oral ingestion the  
4        composition claimed in claim 3.

1 / 1



# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US90/01259

## I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) <sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC  
 INT CL<sup>5</sup> A61K 31/07, 31/355; C07C 35/18, C07D 311/04  
 U.S. CL.: 514/458, 725, 549/408, 568/824

## II. FIELDS SEARCHED

Minimum Documentation Searched <sup>7</sup>

Classification System	Classification Symbols
US	514/458, 725, 568/824, 549/408

Documentation Searched other than Minimum Documentation  
 to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>

## III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup>

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	Chemical Abstracts, volume 109, no. 17, issued 1988, October 24 (Columbus, Ohio, U.S.A.) D. Deng et al., "Effect of -carotene on sister chromatid exchanges induced by MNNG and aflatoxin B <sub>1</sub> in V <sub>79</sub> cells", see page 29, column 2, abstract No. 142177f, Zhonghua Zhongliu Zazhi, 1988, 10(2) 89-91 (Ch)".	1-6
Y	Chemical Abstracts, volume 99, no. 9, issued 1983, August 29 (Columbus, Ohio, U.S.A.) V.N. Rumbesht et al; "Effect of a lipid-soluble vitamin complex on development of induced tumors and certain indices of the body's immune reactivity", abstract no. 69289n, Eksp. Onkol. 1983, 5(3), 42-45 (Russ)".	1-6

\* Special categories of cited documents: <sup>10</sup>

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

18 APRIL 1990

Date of Mailing of this International Search Report

11 JUN 1990

International Searching Authority

ISA/US

Signature of Authorized Officer

*G. S. KISHORE*